Following positive results against template mTSP1, rh-CD47p—as a therapeutic DRP design to antagonize TSP1-initiated detrimental effects—was further investigated under experimental pathological PAH-mimicking conditions (PAH is typically marked by pre-existent excess of TSP1 in circulation) [39]. This evidence concerns the gene THBS1 and pulmonary arterial hypertension.